CA2387247A1 - Use of neutralizing agents to growth factors for reducing wound scarring - Google Patents

Use of neutralizing agents to growth factors for reducing wound scarring Download PDF

Info

Publication number
CA2387247A1
CA2387247A1 CA002387247A CA2387247A CA2387247A1 CA 2387247 A1 CA2387247 A1 CA 2387247A1 CA 002387247 A CA002387247 A CA 002387247A CA 2387247 A CA2387247 A CA 2387247A CA 2387247 A1 CA2387247 A1 CA 2387247A1
Authority
CA
Canada
Prior art keywords
growth factors
composition
neutralizing agents
reducing wound
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002387247A
Other languages
French (fr)
Other versions
CA2387247C (en
Inventor
Mark William James Ferguson
David Michael Foreman
Mamta Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renovo Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10692386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2387247(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2387247A1 publication Critical patent/CA2387247A1/en
Application granted granted Critical
Publication of CA2387247C publication Critical patent/CA2387247C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of said composition and method of administering the composition to a host suffering from tissue wounding is also disclosed.
CA002387247A 1991-03-28 1992-03-30 Use of neutralizing agents to growth factors for reducing wound scarring Expired - Lifetime CA2387247C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9106678.7 1991-03-28
GB919106678A GB9106678D0 (en) 1991-03-28 1991-03-28 Wound healing
CA002105652A CA2105652C (en) 1991-03-28 1992-03-30 Reducing wound scarring with antibodies to growth factors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA002105652A Division CA2105652C (en) 1991-03-28 1992-03-30 Reducing wound scarring with antibodies to growth factors

Publications (2)

Publication Number Publication Date
CA2387247A1 true CA2387247A1 (en) 1992-10-15
CA2387247C CA2387247C (en) 2009-05-19

Family

ID=10692386

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002105652A Expired - Lifetime CA2105652C (en) 1991-03-28 1992-03-30 Reducing wound scarring with antibodies to growth factors
CA002387247A Expired - Lifetime CA2387247C (en) 1991-03-28 1992-03-30 Use of neutralizing agents to growth factors for reducing wound scarring

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002105652A Expired - Lifetime CA2105652C (en) 1991-03-28 1992-03-30 Reducing wound scarring with antibodies to growth factors

Country Status (13)

Country Link
US (4) US5662904A (en)
EP (1) EP0585242B2 (en)
JP (3) JP3333507B2 (en)
AT (1) ATE182792T1 (en)
AU (1) AU661840B2 (en)
CA (2) CA2105652C (en)
DE (1) DE69229729T3 (en)
DK (1) DK0585242T4 (en)
ES (1) ES2136618T5 (en)
GB (1) GB9106678D0 (en)
GR (1) GR3030924T3 (en)
IE (1) IE921013A1 (en)
WO (1) WO1992017206A1 (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5571714A (en) * 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5177197A (en) * 1990-02-27 1993-01-05 Ludwig Institute For Cancer Research Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein
US6197325B1 (en) 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6054122A (en) 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) * 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2123418A1 (en) * 1991-11-14 1993-05-27 Erkki I. Ruoslahti Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
WO1993014782A1 (en) * 1992-01-29 1993-08-05 La Jolla Cancer Research Foundation Methods of controlling the proliferation of macrophages
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
EP1251170A3 (en) * 1992-07-17 2002-10-30 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of NF-kappaB dependent animal diseases
JPH08504763A (en) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド Use of TGF-β receptor fragment as a therapeutic agent
WO1994029452A2 (en) * 1993-06-09 1994-12-22 Ribozyme Pharmaceuticals, Inc. Enzymatic rna molecules and their application in the treatment of fibrosis and fibrous tissue disease
EP0737071A1 (en) * 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US20030130324A1 (en) * 1993-11-19 2003-07-10 Johnston W. Mcavoy Method for preventing or controlling cataract
WO1995016032A1 (en) * 1993-12-09 1995-06-15 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH ANTISENSE NUCLEIC ACID FOR THE TREATMENT OF DISEASES IN WHICH EXPRESSION OF bFGF, PDGF-A OR PDGF-B PLAYS A PATHOGENIC ROLE
CA2184989A1 (en) * 1994-03-07 1995-09-14 Tsvi Goldenberg Ribozyme therapy for restenosis
US5834440A (en) * 1994-03-07 1998-11-10 Immusol Incorporated Ribozyme therapy for the inhibition of restenosis
GB9405046D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
CA2186269C (en) * 1994-03-29 2008-06-03 Mark William James Ferguson Wound healing
GB2288118A (en) * 1994-03-29 1995-10-11 Univ Manchester Wound healing composition
US5824655A (en) * 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB2304045A (en) * 1995-08-04 1997-03-12 Univ Manchester Betaglycan compositions for promoting the healing of wounds and fibrotic diseases
GB2304047A (en) * 1995-08-09 1997-03-12 Univ Manchester Pharmaceutical compositions containing cytokines
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
GB2306481A (en) * 1995-10-21 1997-05-07 Univ Manchester Pharmaceutical comprising a stimulator of activin and/or inhibin
GB9702943D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Wound healing
EP1009421B1 (en) * 1997-08-27 2004-06-30 President And Fellows Of Harvard College Compositions for enhanced wound healing
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6410519B1 (en) * 1999-03-04 2002-06-25 United States Surgical Corporation Scar reduction
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
US6630142B2 (en) 1999-05-03 2003-10-07 Zymogenetics, Inc. Method of treating fibroproliferative disorders
US7261881B1 (en) 1999-05-20 2007-08-28 Yale University Modulation of angiogenesis and wound healing
WO2001027264A1 (en) * 1999-10-15 2001-04-19 Nihon University, School Juridical Person Ribozymes to growth factor originating in human platelet
US6893637B1 (en) 1999-10-21 2005-05-17 Zymogenetics, Inc. Method of treating fibrosis
US20040197333A1 (en) * 2000-02-10 2004-10-07 Cornell Research Foundation, Inc. Use of TGF-beta antagonists to inhibit tumor cell formation or progression
AU9407501A (en) * 2000-06-23 2002-04-22 Medigenes Agent for reduction of scar formation by using wound alkalinization
US6509318B1 (en) 2000-09-29 2003-01-21 The Regents Of The University Of California TGF-B inhibitors and methods
US20020082222A1 (en) * 2000-11-30 2002-06-27 Shapira Nathan Andrew Treatments for neurogenetic disorders, impulse control disorder, and wound healing
US20040235791A1 (en) * 2002-01-25 2004-11-25 Gruskin Elliott A. Scar reduction
GB0217136D0 (en) 2002-07-24 2002-09-04 Renovo Ltd Wound healing & treatment of fibrosis
GB0309064D0 (en) 2003-04-22 2003-05-28 Univ Manchester Modified peptides and their uses
AU2004268614C1 (en) 2003-08-27 2010-10-28 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
AU2004293075A1 (en) * 2003-11-20 2005-06-09 Angiotech International Ag Soft tissue implants and anti-scarring agents
AU2005230848B9 (en) * 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
DE102004025881A1 (en) * 2004-05-19 2006-01-05 Beiersdorf Ag Oligoribonucleotides for influencing hair growth
WO2006029046A2 (en) * 2004-09-03 2006-03-16 Yale University Use of leptin in wound healing
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
WO2007048202A1 (en) * 2005-10-25 2007-05-03 Women's & Children's Health Research Institute Methods and compositions for modulating wound repair
US8353881B2 (en) 2005-12-28 2013-01-15 Abbott Diabetes Care Inc. Infusion sets for the delivery of a therapeutic substance to a patient
US7981034B2 (en) 2006-02-28 2011-07-19 Abbott Diabetes Care Inc. Smart messages and alerts for an infusion delivery and management system
US9119582B2 (en) 2006-06-30 2015-09-01 Abbott Diabetes Care, Inc. Integrated analyte sensor and infusion device and methods therefor
US8206296B2 (en) 2006-08-07 2012-06-26 Abbott Diabetes Care Inc. Method and system for providing integrated analyte monitoring and infusion system therapy management
US8932216B2 (en) 2006-08-07 2015-01-13 Abbott Diabetes Care Inc. Method and system for providing data management in integrated analyte monitoring and infusion system
US8641618B2 (en) 2007-06-27 2014-02-04 Abbott Diabetes Care Inc. Method and structure for securing a monitoring device element
US8085151B2 (en) 2007-06-28 2011-12-27 Abbott Diabetes Care Inc. Signal converting cradle for medical condition monitoring and management system
BRPI0914454A2 (en) * 2008-10-21 2015-10-27 Novodermix Internat Ltd "composition for the treatment of epithelial tissue"
US20120189641A1 (en) 2009-02-25 2012-07-26 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
EP2401613A2 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
CA2921805C (en) 2013-08-22 2023-03-07 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
EP4241848A3 (en) 2017-05-04 2023-11-01 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145676A (en) * 1981-09-08 1992-09-08 The Rockefeller University Method and agents for promoting wound healing
US5104977A (en) * 1982-09-24 1992-04-14 The United States Of America As Represented By The Department Of Health And Human Services Purified transforming growth factor beta
EP0105014B1 (en) * 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
CA1230591A (en) * 1983-06-03 1987-12-22 Charles A. Frolik PURIFIED TRANSFORMING GROWTH FACTOR-.beta. DERIVED FROM HUMAN PLATELETS AND PLACENTAS
DE3629640A1 (en) * 1986-08-30 1988-03-03 Behringwerke Ag USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF TUMORS
US4708948A (en) * 1984-04-20 1987-11-24 The United States Of America As Represented By The Department Of Health And Human Services Substantially purified tumor growth inhibitory factor
DE3588058T3 (en) * 1984-07-16 2005-04-07 Celtrix Pharmaceuticals, Inc., Palo Alto Cartilage-inducing polypeptide factors from bone
US5168051A (en) * 1985-03-22 1992-12-01 Genentech, Inc. Nucleic acid encoding TGF-β its uses
IL78197A (en) * 1985-03-22 1991-07-18 Genentech Inc Nucleic acid encoding tgf-beta and its uses
US4886747A (en) * 1985-03-22 1989-12-12 Genentech, Inc. Nucleic acid encoding TGF-β and its uses
IE60059B1 (en) * 1985-04-19 1994-05-18 Oncogene Science Inc Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US4837381A (en) * 1986-08-11 1989-06-06 American Cyanamid Company Compositions for parenteral administration and their use
US4931548A (en) * 1987-01-30 1990-06-05 Techne Corporation Heterodimer form of transforming growth factor-beta
JPH01502669A (en) * 1987-03-13 1989-09-14 アムジエン・インコーポレーテツド Purified platelet-derived growth factor and its purification method
EP0418234B1 (en) * 1988-06-08 1994-03-23 Genentech, Inc. NUCLEIC ACID ENCODING TGF-$g(b)3 AND ITS USE
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
GB8823649D0 (en) * 1988-10-07 1988-11-16 Geistlich Soehne Ag Chemical compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
IE61346B1 (en) * 1988-11-02 1994-11-02 Genentech Inc A permeable material to fit around the teeth or gums of a mammal
CA2005120A1 (en) * 1988-12-15 1990-06-15 Anthony F. Purchio Tgf-beta 1/beta 2: a novel chimeric transforming growth factor-beta
US5061786A (en) * 1989-05-25 1991-10-29 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
US5118791A (en) * 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
EP0494264B1 (en) * 1989-09-29 1997-06-18 La Jolla Cancer Research Foundation Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
GB8927546D0 (en) * 1989-12-06 1990-02-07 Ciba Geigy Process for the production of biologically active tgf-beta
WO1991010727A1 (en) * 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
US5147854A (en) * 1990-05-22 1992-09-15 Hoffmann-La Roche Inc. Tgf-b compositions and method
JPH05509320A (en) * 1990-06-25 1993-12-22 オーエスアイ　ファーマシューティカルズ，インコーポレイティド Tissue-induced tumor growth inhibitor, its preparation and method of use
US5149801A (en) * 1990-11-21 1992-09-22 The Regents Of The University Of California Boronated porphyrin compounds
GB9101645D0 (en) * 1991-01-25 1991-03-06 British Bio Technology Compounds
AU1426792A (en) * 1991-02-04 1992-09-07 Oncogene Science, Inc. Inhibition of multidrug transport by transforming growth factor beta and uses thereof
GB9106678D0 (en) * 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
AU2738392A (en) * 1991-11-11 1993-05-13 Ciba-Geigy Ag Novel hybrid transforming growth factors
GB9205800D0 (en) * 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
GB9206861D0 (en) * 1992-03-28 1992-05-13 Univ Manchester Wound healing and treatment of fibrotic disorders
EP0737071A1 (en) * 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
CA2186269C (en) * 1994-03-29 2008-06-03 Mark William James Ferguson Wound healing

Also Published As

Publication number Publication date
DE69229729T3 (en) 2007-10-18
IE921013A1 (en) 1992-10-07
US20100152095A1 (en) 2010-06-17
CA2387247C (en) 2009-05-19
AU1436892A (en) 1992-11-02
DE69229729T2 (en) 2000-01-13
JP2006001949A (en) 2006-01-05
JPH06506205A (en) 1994-07-14
EP0585242A1 (en) 1994-03-09
DK0585242T3 (en) 1999-12-06
GR3030924T3 (en) 1999-11-30
ATE182792T1 (en) 1999-08-15
ES2136618T3 (en) 1999-12-01
WO1992017206A1 (en) 1992-10-15
DK0585242T4 (en) 2007-07-02
EP0585242B1 (en) 1999-08-04
GB9106678D0 (en) 1991-05-15
EP0585242B2 (en) 2007-03-07
JP3333507B2 (en) 2002-10-15
ES2136618T5 (en) 2007-10-16
JP2002275094A (en) 2002-09-25
US20050287139A1 (en) 2005-12-29
US20020187149A1 (en) 2002-12-12
DE69229729D1 (en) 1999-09-09
CA2105652C (en) 2005-09-06
CA2105652A1 (en) 1992-09-29
AU661840B2 (en) 1995-08-10
US5662904A (en) 1997-09-02

Similar Documents

Publication Publication Date Title
CA2387247A1 (en) Use of neutralizing agents to growth factors for reducing wound scarring
GB9702943D0 (en) Wound healing
Yarborough Jr Ablation of facial scars by programmed dermabrasion
WO2000051566A8 (en) Scar reduction
WO2000040227A3 (en) Methods for treating conditions associated with the accumulation of excess extracellular matrix
HU9402771D0 (en) Pharmaceutical compositions for wound healing and treatment of fibrotic disorders
CA2387888A1 (en) Local prevention or amelioration of pain from surgically closed wounds
WO2001007067A3 (en) Solutions and methods for inhibition of pain, inflammation and cartilage degradation
EP1555025A3 (en) Use of dehydroepiandrosterone analogs for the treatment of asthma
WO1992016181A3 (en) Composition for promoting tissue repair and regeneration
AU7168587A (en) Two-step procedure for indolent wound healing and aqueous medium and topical ointment used in connection therewith
CA2132416A1 (en) Use of transglutaminase inhibitor for the treatment of scar tissue
CA2221900A1 (en) Use of trospium chloride and 2-component system for the same
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
EP0343807A3 (en) Absorptive adhesive dressing with controlled hydration
GRANT et al. Early management of the burned ear
SE9101840D0 (en) NEW MEDICINAL USE
AU1345000A (en) Irrigation solution and method for inhibition of pain and inflammation
CA2322745A1 (en) Method of treating neuroma pain
CZ223199A3 (en) Use of comt inhibitors or pharmaceutically acceptable salts or esters thereof for preparing a medicament for prevention diabetic vascular dysfunctions
CA2126704A1 (en) Dermatological Compositions and Methods for the Treatment of Skin Therewith
CA2190952A1 (en) Use of a naphthalenesulfonic acid compound for inhibiting retroviral infection
CA2336773A1 (en) Component b as angiogenic agent in combination with human growth factors
RU2003337C1 (en) Wound healing agent
MY118982A (en) Method of reducing tissue damage associated with ischemia

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121211